Developability considerations should be integrated with lead engineering of antibody drug candidates in interest of their cost effective translations into medicines. To explore feasibility of this imperative, we have performed rational mutagenesis studies on a monoclonal antibody (MAB1) whose development was discontinued owing to manufacturability hurdles. Seven computationally designed variants of MAB1 containing single point (V44K, E59S, E59T and E59Y) and double (V44KE59S, V44KE59T and V44KE59Y) mutations in its light chain were produced in Chinese Hamster Ovary (CHO) cells and purified by using platform processes employed during commercial scale production of monoclonal antibodies. MAB1 and its variants were formulated in the same platform buffer and subjected to a battery of experiments to assess their solution behaviors, and biological activities. Five of the seven (71%) variants of MAB1 demonstrated improved biophysical attributes in multiple experimental testings. Contrary to the commonly expressed reservations about potential biological activity loss upon developability optimizations, the improvements in solution behavior of MAB1 also increased its biological activity up to~180%. In particular, concentrate-ability and apparent solubility of V44KE59S improved to~150% and~160%, respectively. Its diffusion interaction parameter (k D ) reduced to 28% and viscosity at~100 mg/ml decreased to less than half of the corresponding values for MAB1. V44KE59S is also slightly more active and its transfections in CHO cells were more productive. It also degraded slower than MAB1 in three month long 25°C and 40°C formulation stability studies. These results open doors to an exciting realm of structure-based biologic drug design where developability and biological activity can be simultaneously optimized at the molecular engineering stages.
Introduction
Biologics, particularly, monoclonal antibodies (mAbs) have emerged as the most successful class of pharmaceuticals over the past couple of decades. However, merely 18% of potential biologic drug candidates discovered in research laboratories are able to overcome all challenges involved in their drug product development and successfully reach the clinic (Smietana et al., 2016) . Low translation rates coupled with relatively high development costs due to more complex manufacturing processes and more stringent regulatory requirements make commercialization of biologic drug products a particularly risky affair (Zurdo, 2013; . In the drug discovery stages of a project, focus deserves to be on biological activities of the potential biologic drug candidates. Candidates that show greater potencies are often prioritized over others. In addition to biological activity, however, sequence-structural properties of biologic drug candidates can also inform us about potential challenges encountered during the drug product development stages . Almost all challenges and hurdles encountered during manufacturing, safety and in vivo performance testing of biologic drug candidates can be traced back to their sequence-structural attributes. Unfortunately, amino acid sequence of a biologic drug candidate gets locked at the discovery stage and cannot be changed during subsequent drug product development stages. This cumulative experience has prompted biopharmaceutical industry to embrace the concept of developability in biologic drug discovery and development (Zurdo, 2013; Jarasch et al., 2015; Kumar et al., , 2018 Steffen Hartmann, 2016; Yang et al., 2017) .
A major hurdle in implementing rigorous developability assessments at the discovery stages of a project is the limited availability of material for experimental testing and large number of potential candidates to assess depending on how far the project has progressed. Therefore, a significant opportunity exists for developing and applying computational tools towards the biologic drug developability assessments. Computational tools are inherently faster and require no material. They are therefore ideally suited for such analyses. It should also be stated here that the computational tools can be, in fact, applied at all stages of biologic drug discovery and development cycles and this includes late stage development, in-licensing and commercialization. Computational analyses have been shown to yield novel insights into properties of the biologic drug candidates when combined with high quality data collected from experiments performed under standardized conditions (Li et al., 2014; Sharma et al., 2014; Jain et al., 2017; Tomar et al., 2017) . Therefore, a strategic vision, Biopharmaceutical Informatics (Kumar et al., 2017) , calls for synergistic use of experimentation (e.g., biophysical experiments, cell-based bioassays, cell line expression, bioprocessing, purification and formulation stability studies) and computation (e.g., database creation, informatics, molecular modeling, statistical analyses, machine learning and artificial intelligence) to enable structure-based biologic drug design. Insights gained by utilizing Biopharmaceutical Informatics approaches at early stages of lead candidate design and selection can help make discovery and development of biologic drugs more efficient by removing empiricism, reducing development costs and improving translation rates .
At the heart of Biopharmaceutical Informatics lies our ability to connect microscopic molecular sequence-structural attributes of biologic drug candidates with their macroscopic experimental behaviors such as biological activity, pharmacology, thermodynamic stability, solubility, viscosity; and capacity to withstand stresses experienced during manufacturing and maintain molecular integrity (formulation stability) . The idea that such connections between microscopic and macroscopic aspects of proteins exist has been well accepted and the literature describes two approaches to probe them: First approach is to perform statistical analyses of the experimental data obtained on a set of biological macromolecules to understand how their macroscopic behaviors can be rationalized in terms of molecular properties computed from their amino acid sequences and structures. Such database analyses involve derivation of empirical correlations among experimentally measured and calculated biophysical attributes. The derived correlations can be then used to estimate biophysical attributes of additional biological macromolecules similar to those in the training set. The reader is referred to Li et al. (2014) , Agrawal et al. (2016) , Tomar et al. (2017) , Sharma et al. (2014) and Jain et al. (2017) for recent applications to this approach towards development of antibody based therapeutics. The second approach involves attempts to improve macroscopic behavior of a given biologic macromolecule via rational mutagenesis. Examples of the second approach include the work from Yadav et al. (2012) Nichols et al. (2015) , Geoghegan et al. (2016) and Laber et al. (2017) . These two approaches are not mutually exclusive; rather they are complementary to each other. In this report we apply the second approach to improve solution behavior of a monoclonal antibody via rational optimization.
As described in an earlier report, solution behavior of a Pfizer proprietary antibody (MAB1) with several product development challenges was improved via two computationally designed single point mutations at positions 44 and 59 in its λ light chain (Nichols et al., 2015) . The two point mutations were designed in such a way that one of them (V44K) disrupted an aggregation prone region (APR) and removed a solvent exposed hydrophobic patch; and the other one (E59Y) neutralized a negatively charged patch. The point mutation V44K improved apparent solubility of MAB1, while E59Y reduced its viscosity at high concentrations. In this work, we use the same light chain positions for mutagenesis but expand the scope of our analyses to include the combinations via double mutations. Additional residues Ser and Thr were also tried at the E59 position, since E59Y point mutation succeeded in lowering viscosity in the previous study (Nichols et al., 2015) . Side chains of both these residues also contain hydroxyl groups like in Tyr side chain. In total, eight monoclonal antibodies, MAB1 and its seven mutants (V44K, E59Y, E59S, E59T, V44KE59Y, V44KE59S and V44KE59T), were produced in CHO cells. All the eight antibodies were purified and formulated using standardized experimental protocols, which mimic in-house commercial scale antibody manufacturing processes. All of them were also subjected to identical biophysical and bioactivity analyses. Surprisingly, improvements in biophysical attributes of MAB1 were accompanied by improvements in its biological activity. Our observations contest commonly expressed pushback to optimizing lead antibody candidates for developability because of potential loss in biological activity.
Experimental Procedures
Amino acid sequence of MAB1 and identification of mutation sites
Complete amino acid sequence of MAB1 has been already disclosed in the patent WO/2004/037861. Below we provide the sequence of the light chain of the MAB1 with mutation sites highlighted in bold font. The CDRs are underlined. Note that the mutation sites are present in the framework regions 2 and 3 of the light chain.
>MAB1-LC

SYELTQPPSVSVSPGQTASITCSGHALGDKFVSWYQQKPGQ-SPVLVIYDDTQRPSGIPERFSGSNSGNTATLTISGTQAMDEA-DYYCQAWDSSFVFGGGTKVTVLGQPKAAPSVTLFPPSSEEL-QANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSK-QSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTV-APTECS
Mutations studied in this report are V44K, E59Y, E59S, E59T, V44KE59Y, V44KE59S and V44KE59T
Computational methods
Estimation of free energy change upon mutation in MAB1 A homology based molecular model for full length MAB1 was generated and optimized via energy minimizations by using MOE2014.09 from Chemical Computing Group (https://www.chemcomp.com/) and procedures described in Guo et al. (2014) . Briefly, a chimeric template constructed from crystal structure of the human b12 antibody (PDB entry 1HZH; Saphire et al., 2001 ) and a molecular model of the Fab region of MAB1 (generated using the procedure similar to the one described earlier in Nichols et al. (2015) for Fv modeling) was used to generate 1000 intermediate models (100 backbone models and 10 side chain models per backbone) with the glycan positions in 1HZH used as 'induced fit'. The intermediate models were ranked according GB/VI solvation. The best ranking model was selected and further optimized for improved stereochemistry via energy minimizations using AMBER10:EHT force field. The final model was protonated for pH 6.0 and zero ionic strength and optimized again to root mean square gradient (RMSG) below 0.001 kcal/mol/Å 2 . The 'Residue Scan' module in MOE was used to estimate the free energy change upon mutation in full length model of MAB1. The procedures for creating the mutation, generating the conformer ensembles and estimating the free energy change have been described in details in MOE help pages. Briefly, creation of each mutation involved repacking of all residues within 9 Å of the site of mutation and optimization of the local structure to RMSG below 0.001 kcal/mol/Å 2 at pH 6.0.
Each mutation procedure involved generation of up to 100 conformers via 1000 ps equilibrated MD simulations. Residues farther than 10 Å from the mutation site were fixed in these simulations. Note that each antibody contains two light chains and two heavy chains. The mutations were made in both the light chains.
MD simulations of the Fv portions of MAB1 and its variants
Atomic coordinates for residues belonging to the Fv portion of MAB1 were extracted from the full length model of MAB1 and C-termini of both Heavy and Light chains were capped with N-methyl amide group (NME). MAB1 Fv model was then energy minimized to an RMSG below 0.00001 kcal /mol/Å 2 . The following mutations were made in the light chain of the MAB1 Fv: V44K, E59S, E59T, E59Y, V44KE59S, V44KE59T and V44KE59Y leading to the seven Fv variants. Structures of MAB1 Fv variants were then energy minimized to an RMSG below 0.00001 kcal/mol/Å 2 . All the Fv models were then solvated in a cubic box and energy minimized to RMSG below 0.1 kcal/mol/Å 2 and neutralized via addition of chloride ions. All these manipulations were performed in MOE to generate input files for MD simulations. AMBER10 force-field for protein and TIP3P forcefield for water molecules were used throughout this study. The MD simulations were performed in NAMD (Phillips et al., 2005) at a temperature of 300 K and pressure of 1 bar. Two independent 20 nanoseconds trajectories were run for each Fv model. Van der Waals interactions were truncated at 12 Å with a smooth truncation beginning at 10 Å. Particle Mesh Ewald (PME) method was used for electrostatic interactions and a time step of two femtoseconds was used. Data obtained from the MD simulation trajectories was used to study coordination of water molecules by the residues at the mutation sites within the first hydration shell. Numbers of unique water molecules within 5 Å for the heavy atoms of the residues at light chain positions 44 and 59 were computed for MAB1 and its variants. 
Experimental methods
MAB1
Purification of MAB1 and variants
The purification train for MAB1 and its mutants is a multi-step process designed to separate the antibody from a variety of process derived impurities and achieve concentration and formulation of the final drug substance. In the first step, clarified conditioned media was loaded onto a MabSelect Protein A affinity column. The product pool then flowed through a TMAE anion exchange column while additional impurities including leached protein A -antibody complex remain bound to the resin. The product pool then flowed through a hollow fiber filter which allows protein to flow through while retroviral-like particles are retained. A ceramic hydroxyapatite chromatography (CHA) step then removed the high molecular weight aggregates and other impurities such as DNA. The CHA elution pool was processed through a tangential flow ultrafiltration system in which the antibodies were concentrated and diafiltered into formulation buffer 20 mM histidine/histidine-HCl, 5% (w/v) sucrose at pH 6.0.
Apparent solubility by PEG precipitation
The apparent solubility measurements were performed using a PEG precipitation method as described earlier (Nichols et al., 2015) with minor modifications. A 38% (w/w) PEG stock solution was prepared by dissolving PEG 12 k into 20 mM histidine/histidine-HCl buffer, pH 6.0. The antibody solutions were diluted to a protein concentration of 5 mg/ml using the same buffer. From solutions of antibodies, 100 μl samples were used for this analysis. Aliquots of the stock PEG solution were pipetted into each sample, 1 μl at a time. Each antibody sample and PEG aliquot was thoroughly mixed by pipetting the solutions up and down, so as to avoid subjecting the mAb to unnecessary shear stress. Additional aliquots of PEG were added until the antibody started to precipitate. The minimum amount of PEG required to cause precipitation (determined via visual inspection) of the antibody was then calculated and used as a relative apparent solubility score for the antibody sample. The measurements were repeated thrice for each antibody solution.
Concentrate-ability
To assess the protein's ability to concentrate, MAB1 and its variants were concentrated up to 80-160 mg/ml using Millipore Amicon Ultra-4 Centrifugal Filters, 10 000 NMWL cut off. The centrifugation was performed at 3000 revolutions per minute (rpm) at 25°C. Periodically, the concentrate was mixed by pipette and the protein concentration was checked using a SoloVPE spectrometer from C Technologies, Inc.
Differential Scanning Calorimetry (DSC) DSC experiments were performed using a TA Instruments model Nano DSC with a scan rate of 1°C/min over the temperature range of 35-95°C. The NanoAnalyze software was used to process the data by subtracting the thermogram of the formulation buffer (20 mM histidine/histidine-HCl, 5% (w/v) sucrose, pH 6.0) from the thermogram of the sample. The thermal transitions were then deconvoluted and model fit to determine the midpoints (T m ) of the three thermal events.
Size Exclusion Chromatography (SE-HPLC) SE-HPLC was performed on an YMC-Pack Diol -200 column, 300 mm × 8 mm ID using a mobile phase of 20 mM sodium phosphate, 400 mM sodium chloride and pH 7.2. The flow rate was 0.75 ml/min, the column temperature was set to 30°C, and the sample temperature was set to 5°C. Absorbance was monitored at 280 nm over the course of the 20 min run time. Samples were diluted to 2 mg/ml in mobile phase and 50 μg of protein from each sample was loaded onto the column per injection. Instrumentation included Water's e2695 separations module equipped with Water's 2489 UV/Vis detector. Empower 3 software (build 3471) was used for data acquisition and analysis.
Hydrophobic Interaction Chromatography (HIC-HPLC) HIC-HPLC was performed on two Dionex ProPac HIC-10 (100 mm × 4.6 mm ID) columns in series. Gradient separation was performed using a mobile phase A of 1 M ammonium sulfate, 20 mM sodium acetate, pH 5.5 and a mobile phase B of 20 mM sodium acetate, 10% acetonitrile, pH 5.5. The flowrate was 0.6 ml/min, the column temperature was set to 30°C, and the sample temperature was set to 20°C. Absorbance was monitored at 280 nm over the course of the 65 min run time. Samples were diluted to 2 mg/ml in Milli-Q water and then mixed 1:1 (v/v) with 2 M Ammonium sulfate for a final concentration of 1 mg/ml in 1 M Ammonium sulfate. A total of 100 μg of protein from each sample was loaded onto the column per injection. Instrumentation included Waters e2695 separations module equipped with Waters 2489 UV/Vis detector. Empower 3 software (build 3471) was used for data acquisition and analysis.
Dynamic Light Scattering (DLS)
The dynamic light scattering experiments were performed using the same protocol as described earlier (Nichols et al., 2015) . Briefly, diluted solutions (2-10 mg/ml concentration range) of MAB1 and variants were prepared in the same formulation buffer (20 mM Histidine/Histidine-HCl buffer, 5% (w/v) sucrose, pH 6.0). The measurements were performed using a Dynapro Plate Reader II (Wyatt Technology) and data analyzed using Dynamics V7.1. Viscosity Viscosity data were generated for MAB1 and its variants in formulation buffer of 20 mM histidine/histidine-HCl, 5% (w/v) sucrose, pH 6.0. MAB1 and its variants were spiked with 80% sucrose and dialyzed into an offset buffer (30 mM histidine, pH 5.8) to achieve a final pH of 6.0. All the solutions were then concentrated by centrifugation to approximately their solubility limit, after which they were diluted serially in formulation buffer prior to viscosity measurements. Experiments were performed using a RheoSense model m-VROC™ maintained at 20°C using chip types A and B for low and high viscosity samples respectively. Samples were centrifuged briefly for the removal of air bubbles and then injected onto the chip using a 100 μl Hamilton Model 1710 Gastight syringe. The m-VROC Control Software was used for data acquisition and analysis.
Biological activity
Biological activities of MAB1 and its variants were studied using ELISA and cell-based bioassays. The ELISA method has been already described in our previous report (Nichols et al., 2015) . Hence, only the cell-based bioassay is described below. This bioassay uses an adherent epithelial cell line derived from a human sarcoma. It has a receptor expressed on the tumor cell surface to which the antigen recognized by MAB1 binds. The cells were stably transfected with a luciferase reporter vector containing the desired DNA sequence. These cells were seeded into 96 well plates at a concentration of 20 000 cells per well and then incubated for~24 h to allow cell attachment. The final concentration-response curve for each MAB1 variant was prepared in the range of 28 -2000 ng/ml. Pfizer proprietary target antigen was prepared at a final concentration of 50 ng/ml and pre-incubated with the MAB1 variants for 30 min to allow for binding. The media was removed from the cells, the MAB1 variant-antigen mixture was then added to the cells and the 96 well plates were incubated for 5-6 h. During this incubation, unbound antigen was available to engage the target receptor on the cell surface initiating signaling events that result in activation of luciferase reporter gene. The cells were then lysed and a luciferase substrate was used to quantitate the cellular response. Higher concentrations of MAB1 variants yielded a decrease in luminescence signal because fewer antigen molecules are available for receptor engagement. The relative luminescence signal intensity of each plate well was measured using a luminescence plate reader.
Results
This work builds on our earlier report (Nichols et al., 2015) and presents new data on our efforts to improve solution behavior of MAB1 via rationally designed mutations. Molecular modeling had helped identify two residue positions in the light chain (LC) of MAB1 whose product development was discontinued because of opalescence, aggregation, viscosity and immunogenicity hurdles (Nichols et al., 2015) . Locations of these positions in the Fv portion of MAB1 are shown in Fig. 1 . The first position, V44, is located near V L :V H interface and is part of an aggregation prone region (APR) as well as a solvent exposed hydrophobic patch. A single point mutation V44K disrupted the APR as well as the hydrophobic patch and this resulted in increased solubility for MAB1. The second position E59 is a solvent exposed negatively charged patch. The mutation E59Y neutralized this patch and this resulted in reduced viscosity for MAB1 at high concentrations (Nichols et al., 2015) . These same light chain positions were further interrogated via mutagenesis in the current work. This time double mutations were also designed and the following variants of MAB1 were tested experimentally: V44K, E59Y, E59S, E59T, V44KE59Y, V44KE59S and V44KE59T. Salient observations from this study are described below.
Estimations of free energy change in conformational stability of MAB1 upon mutations A full length homology based model of MAB1 was used to estimate how mutations might impact conformational stability of MAB1 via free energy change calculations as described in Materials and Methods. Values for the change in the isoelectric point (ΔpIsequence) for the variants as compared to the parent MAB1 were also estimated by using the amino acid sequences of MAB1 and its variants. Table I summarizes results from both of these calculations. All variants of MAB1 are expected to have similar pI as MAB1. The free energy calculations suggest that single point mutations V44K (ΔΔG stability = +1.69 kcal/mole) and E59T (ΔΔG stability = +3.77 kcal/mole) are expected to be destabilizing, while E59Y (ΔΔG stability = −3.22 kcal/mole) and E59S (ΔΔG stability = −2.04 kcal/mole) are expected to stabilize MAB1. Among the three double point mutations, V44KE59Y (ΔΔG stability = −2.2 kcal/mole) is expected to be stabilizing and V44KE59T (ΔΔG stability = +4.78 kcal/ mole) is destabilizing to MAB1. The double mutant V44KE59S is not expected to affect the stability of MAB1 (ΔΔG stability = +0.15 kcal/mole). Furthermore, the two LC mutation sites appear to be cooperative, i.e., the calculated ΔΔG stability values for the three double mutants differ from those obtained by adding the ΔΔG stability values for their component single point mutations. However, cooperativity between the two sites is weak because calculated and expected values differ only by 0.5-0.7 kcal/mole ( Table I ). Note that the variants containing Thr at position 59, V44KE59T and E59T, were taken forward for experimental testing despite their significantly destabilizing effect on MAB1 to obtain a well-rounded testing of the computational designs.
Production of MAB1 and its variants
MAB1 and its variants were transfected in CHO cells and the transfection pools generated were tested for their peak cell density, viability, titer and specific productivity in each case. Table II summarizes data on performance of transfection pools for MAB1 and its variants. All transfections were performed in duplicates. Upon transfection, all pools recovered within 16-23 days, except for one duplicate for the double mutant V44KE59S. No significant differences were observed in recovery times of any specific mutant or wild-type expressing pools. Transfection pools for MAB1 and all its variants yielded antibody titers in the range of 600-1000 mg/l. Specific productivity (Qp) of MAB1 variant transfection pools ranged from 8 to 12 picograms/ cell/day. Transfection pools of the parent antibody (1A and 1B) yielded Qp values of 9 picograms/cell/day. Interestingly, all except one variant transfection pool (4B, E59Y) yielded greater Qp and antibody titer values than those for the parent MAB1 (Table II) . These observed improvements in performance of the variant transfection pools over the parent MAB1 should be interpreted with caution, since only two transfections per variant were performed in this study. The following transfection pools were taken up for production and purification: 1A -MAB1; 2B -V44KE59S; 3A -V44KE59Y; 4A -E59Y; 5B -E59T; 6B -E59S; 7A -V44K; and 8B -V44KE59T (Table II) . Platform experimental procedures and technologies similar to those employed during drug product development of monoclonal antibodies were followed here (Materials and methods). Production of the antibodies in CHO cells and use of drug product development stage processes are major improvements in this work over the previous study (Nichols et al., 2015) . These experiments yielded~500 mg of highly pure (>95%) material for MAB1 and each of its variants. These materials were used for experiments aimed at assessing solution properties, formulation storage stabilities and biological activities of MAB1 and its variants.
Thermal stability of MAB1 and its variants Fig. 2 presents the overlays of DSC thermograms for MAB1 and its variants. These results show that all single point and double mutants follow similar thermal melting profiles. The three melting temperatures (T m 1, T m 2 and T m 3) are similar for all variants, except V44KE59Y and E59Y. In case of these variants, the first melting temperature (T m 1) decreased by~2°C from 69°C to 67°C (Fig. 2) . These observations are similar to our earlier observation of decrease in T m 1 for E59Y mutation to MAB1 (Nichols et al., 2015) . While this drop is significant, the T m 1 values for V44KE59Y and E59Y are still~67°C, indicating high thermal stability. Therefore, these variants were not excluded from further experimentation. It should also be mentioned here that the thermal stabilities of MAB1 and its variants assessed via melting temperature in DSC thermograms do not follow the same trend as that for calculated free energy change upon mutation values for MAB1. Specifically, conformational destabilization predicted for the variants E59T and V44KE59T (ΔΔG values in Table I ) did not lead to lower T m values for these variants in the DSC experiments (see Fig. 1 ). This observation can be rationalized as follows. In case of natively folded proteins with well-defined three-dimensional conformations, the relationship between free energy change (ΔG) and melting temperature (T m ) is nonlinear. These quantities are related to each other via the Gibbs-Helmholtz equation which also involves two additional thermodynamic parameters, namely, change in enthalpy (ΔH) and change in heat capacity (ΔCp) (Kumar et al., 2001 ). Experimentally measured thermodynamic data for small single domain reversible two state proteins shows that proteins with similar melting temperatures can have significantly different free energy values at the room temperature (Kumar et al., 2002) . Antibodies are much larger proteins with multiple structural domains and multiple thermal transitions. Therefore, it is not surprising if ΔΔG values in Table I and T m values in Fig. 2 do not correlate.
Appearance, hydrophobicity, concentrate-ability, apparent solubility of MAB1 and its variants MAB1 forms clear solutions at room temperature, but demonstrates phase separations and gelation when stored at 2-8°C (Nichols et al., 2015) . To study the impact of point mutations on appearance of MAB1 solutions, appearance testing was performed for highly concentrated (≥150 mg/ml) solutions of MAB1 and its variants at 21°C and 2-8°C ( Fig. 3A and B) . Fig. 3A shows that all the antibody solutions are clear at 21°C, except for the mutations involving Thr, namely, E59T and V44KE59T (Fig. 3A) . At 2-8°C, solutions of MAB1 variants V44KE59Y, E59Y and V44K were clear, while those of the variants E59S, V44KE59S, E59T and V44KE59T were turbid (Fig. 3B) . A sample of MAB1, from a previously manufactured GMP lot, was used as a control for these experiments. Table III shows concentrate-ability, apparent solubility, water coordination and hydrophobicity data for MAB1 and its variants.
Hydrophobicity of MAB1 and its variants was assessed by comparing the retention times in a hydrophobic interaction chromatography (HIC) column (Materials and Methods). All mutants, except E59Y and V44KE59Y, showed similar retention times as the parent MAB1 (retention times range = 24.60-24.99 min). The retention times for MAB1 variants E59Y (28.14 min) and V44KE59Y (27.88 min) increased by~3 min; probably due to presence of an aromatic residue at the solvent exposed position 59.
Each antibody solution was concentrated by spin centrifugation at 3000 rpm at 25°C for 50 min and its concentration was measured at the end of the centrifugation (Materials and Methods) to assess improvements in concentrate-ability of the MAB1 variants. An increased concentration value for a MAB1 variant as compared to To understand whether the two LC sites (V44) and (E59) are independent of each other, the free energy change upon single point mutations at each site were added together for the double mutants. Note that additive values and calculated values of ΔΔG stability (kcal/mole) differ by 0.5-0.7 kcal/mole in magnitude for the three double mutants. These observations suggest that the two sites may be weakly cooperative and effects on mutations at these sites may be synergistic. NA means not applicable. the parent MAB1 shows improved ability to concentrate the variant. It can be seen that all variants except E59T and V44KE59T performed better than the parent antibody (Table III) . The apparent solubility measurements for MAB1 variants were performed using a PEG precipitation method (Materials and Methods). Increase in %PEG required to precipitate the protein serves as an indicator of increased apparent solubility for the variants of MAB1. Table III shows that all variants of MAB1 showed improved apparent solubilities.
Taking together, the data presented in Table III suggests that MAB1 variants perform better than the parent MAB1 in regard to concentrateability and apparent solubility, even though their hydrophobicities do not change much. In general the double mutants could be concentrated more and have greater apparent solubilities than the single point mutants. Interestingly, the synergistic effect of the double mutation appears to have a direction when it comes to improvements in concentrate-ability and apparent solubility. Addition of V44K mutation to E59Y, E59S and E59T mutations consistently leads to improvements in concentrate-ability and apparent solubility for the double mutants (Table III) .
We hypothesized that macroscopic differences in concentrateability and apparent solubility of MAB1 and its variants should arise from a combination of three microscopic factors: (i) Intrinsic solubilities of the amino acids at the mutation sites; (ii) ability to coordinate water molecules by residues at mutation sites within the structural context of the antibody; and (iii) formation of intermolecular (protein-protein) interactions by MAB1 and its variants in both dilute and high concentration regimes. One must bear in mind that these factors are related to one another. It is well known that Lys is more soluble in water than Val (mutations involving V44K). Similarly, Ser and Thr are more soluble but Tyr is less soluble in water than Glu (see https://www.anaspec.com/html/amino_ acids_properties.html). Therefore, trends in the intrinsic solubilities of the residues at positions 44 and 59 in the light chain of MAB1 do not completely explain improved apparent solubilities for E59Y and V44KE59Y.
To study water coordination ability of the residues at mutation sites, average numbers of water molecules within 5 Å distance of the heavy atoms of these residues were calculated by using data obtained from all atom explicit water molecular dynamics simulation trajectories. These simulations were performed on the Fv portions of MAB1 and its variants (as described in Materials and Methods). Two MD simulation trajectories, each 20 ns long, were collected for MAB1 and its variants. Positions of the oxygen atoms in water molecules were used to compute these distances. Choice of 5 Å as a distance cut off between water molecules and residues at the mutation sites is arbitrary. It was used as a qualitative measure to study water coordination in the first hydration shell (Tomar et al., 2016) . Average numbers of water molecules coordinated by the residues at the mutation sites are also presented in Table III . It can be seen that mutation of V44 to K44 in all MAB1 variants results in increased number of water molecules around K44. The average numbers of water molecules around K44 fall in the range~17-19 among the variants V44K, V44KE59S, V44KE59Y and V44KE59T. In comparison, the average numbers of water molecules around V44 range from 12 to 14 in the parent MAB1 and variants E59S, E59Y and E59T. This trend remained consistent even when the numbers of water molecules coordinated by the residues at the position 44 were normalized by the residue sizes i.e., the numbers of heavy atoms in the residues at the position 44. K44 (1.69-1.93 water molecules per heavy atom) shows improved ability to coordinate water than V44 (1.48-1.70 water molecules per heavy atom, Table III ). This observation can be rationalized by taking into account the differences in chemical natures of Lysine versus Valine. However, the situation is more complicated in case of mutations at E59 position. Average numbers of water molecules coordinated by S59 and T59 decreased in comparison to those coordinated by E59. On average E59 coordinated~26 water molecules, while S59 coordinated 18 and T59 coordinated 20 (Table III) . However, Ser and Thr are smaller in size than Glu and normalization by the number of heavy atoms revealed that Ser and Thr have similar water coordination abilities as Glu (range: 2.53-2.65 water molecules per heavy atom, Table III ). In comparison, Y59 coordinates only~2.2 water molecules per heavy atom, even though it coordinates~29 water molecules (Table III) . Again, trends in ability to coordinate water by the residues at position 59 are not consistent with trends in apparent solubility and concentrate-ability of the MAB1 variants involving Tyr mutations at the position 59, neither singly nor in combination with V44K mutation (Table III) . However, this conclusion should be tempered by noting that MD simulations performed here were short and limited to the Fv Fig. 3 Appearance of highly concentrated (>150 mg/ml) solutions of MAB1 and its variants at 21°C (A) and 2-8°C (B). portions only. Dependence of water coordination numbers on simulation length was not studied in this work. However, Figure S1 in the supplementary material suggests that the number of water molecules coordinated by the residues at the mutation sites remains fairly constant for the parent MAB1 and the variant that showed significantly improved water coordination number, namely, V44K. Other variants also showed similar trends.
Next, the effects of mutations in MAB1 on its protein: protein interaction attributes and changes in solution properties of MAB1 were probed here by studying diffusion properties of MAB1 and its variants in dilute concentration regimes (2-10 mg/ml) and viscosities in high concertation regimes (≥100 mg/ml). The following section compares the diffusion and viscosity properties of MAB1 and its variants.
Viscosity and diffusion properties of MAB1 and its variants
Concentration dependent viscosity measurements were performed for MAB1 and its variants by using mVROC rheometer on a chip as described in materials and methods. At least three independent measurements were performed and averaged for each concentration. At the concentrations~150 mg/ml and higher, the three independent measurements yielded significantly different viscosity values in case of several variants. Averaging the data from such measurements led to large standard deviations. A portion of the large variability in the viscosity values might have been due to the entrainment of very small air bubbles in the mVROC capillaries. These bubbles were difficult to separate from the viscous liquid phase despite centrifugation. In case of some variants, particles were also observed at the capillary outlets. These measurements were discarded and not used for interpreting the results in this report. Table IV presents viscosity values at concentrations~100 mg/ml for MAB1 and its variants. The viscosity measurements at~100 mg/ ml concentration were more precise as reflected in relatively small standard deviations (~1 cP or smaller). Furthermore, differences in viscosity values among the MAB1 variants are also well separated at this concentration, facilitating reliable interpretation of the results (Table IV) . High concentration solutions of MAB1 variants that involve substitutions of Ser or Tyr at position 59 consistently demonstrate lower viscosities than that the parent antibody, both as single point mutations and as double mutants. In particular, V44KE59S, E59S and V44KE59Y demonstrate viscosities that are reduced by at least 50% when compared to the parent MAB1 at~100 mg/ml (Table IV) . Viscosity of high concentration solution of V44KE59S is the lowest among all variants (9.6±0.01 cP at 96.2 mg/ml, Table IV ). Note that solution viscosity for the variant V44KE59T was not determined because it could not be concentrated up to 100 mg/ml in reasonable quantities required for the measurements (Table IV) . 
MAB1 variant
Viscosity (cP) at conc.~100 mg/ml 
11.4 a n.d. stands for not determined. The viscosity measurements were performed using mVROC rheometer on a chip. While these measurements were performed at several concentrations, the data are shown only for the concentrations~100 mg/ml. The actual concentration value measured using solo-VPE is shown in parenthesis. Viscosity for the variant V44KE59T could not be determined because it could not be suitably concentrated in quantities needed for the viscosity experiments. DLS measurements of concentration dependent diffusion behaviors for the MAB1 variants E59T and V44KE59T were unusable for linear fitting. Therefore D 0 and k D values could not be determined. The data on Apparent solubility of the variants are also shown from Table III. Dynamic light scattering (DLS) experiments were performed to study the diffusion properties of MAB1 and its variants under dilute conditions (concentrations: 2-10 mg/ml) by using the same experimental protocols as described in our earlier report (Nichols et al., 2015) . Results from these experiments are also summarized in Saltzman et al. (1994) and those for other Pfizer proprietary mAbs (Tomar et al., 2017) . The diffusion interaction parameter (k D ) values for the variants of MAB1 were compared with that of the parent MAB1 by computing the ratio k D -variant/k D -parent. All MAB1 variants show smaller k D values compared to the parent MAB1 (k D = −21.9 ml/g for parent MAB1, Table IV ). The greatest improvements were observed for the variants involving substitution of Glu 59 by Ser. The k D for V44KE59S is −6.15 ml/g. It is 28% of the k D for the parent MAB1; a reduction by 72%. The k D for E59S is −9.1 ml/g; 42% of the k D for the parent MAB1 and a reduction by 58%. Tessier and coworkers (Jayaraman et al., 2014) have used k D values of~−9.0 ml/g (range: −8.9 to −8.2 ml/g) as cut-offs to interpret inter-molecular associations formed by IgG molecules as being attractive or repulsive. Therefore, the inter-molecular interactions for MAB1 and all its variants are expected to be attractive, except those for the variant V44KE59S. Interestingly, the intermolecular interactions formed by the single mutations V44K (k D = −19.5 ml/g) and E59S (k D = −9.1 ml/g) fall in the attractive regime, while those formed by the double mutant V44KE59S are weakly repulsive (k D = −6.15 ml/g). These observations demonstrate the benefits of synergies among the two mutation sites. The MAB1 variants involving substitution of Glu 59 with Tyr, namely, V44KE59Y and E59Y also show improvements in their k D values, although to smaller extents. The k D for V44KE59Y is −12.1 ml/g, a reduction of 45% as compared to the k D value for the parent MAB1 (−21.9 ml/g). Similarly, k D for the variant E59Y is −15.3 ml/g, a reduction of 30%. The decreases in the k D values of V44KE59Y and E59Y are consistent with the improvements in apparent solubilities for these variants. Note that D 0 and k D values for MAB1 variants E59T and V44KE59T could not be obtained because the concentration dependent diffusion plots for them were multimodal and determined to be unsuitable for linear fitting by instrument's software.
Table IV also includes the apparent solubility values from Table III in case of MAB1 and its variants for which DLS and viscosity experiments yielded results to facilitate a multi-attribute comparison of antibody solution properties. The rows in Table IV have been sorted by ratio k D -variant/k D -parent. We found that this ratio is a useful estimate of improvements in solution properties of MAB1 variants. Reductions in viscosity at 100 mg/ml and increases in apparent solubilities correlate with this ratio and also with each other in most, but not in all cases. These observations are consistent with our recent findings from a different study on 16 different drug product development stage monoclonal antibodies which showed that k D is a key property for antibody formulations because it correlates with their multiple biophysical attributes (Tomar et al., 2018) . Furthermore, the synergistic effects seen for the double mutations in case of concentrate-ability and apparent solubility are also observed in case of k D and viscosity. Addition of V44K mutation to E59S and E59Y leads to significant improvements in diffusion and viscosity behaviors of the double mutants (Table IV) .
In summary, diffusion and viscosity experiments show that protein: protein interactions formed in the solutions of MAB1 have been reduced significantly for its variants involving mutations V44K, E59Y and E59S both singly and in combinations of V44K with E59S and E59Y. In particular, the variant V44KE59S has significantly improved solution properties in both dilute and high concentration regimes. The self-association tendencies of the variants E59T and V44KE59T, however, worsened as compared to MAB1.
Taking together the results from concentrate-ability, apparent solubility, diffusion and viscosity behaviors of MAB1 and its variants, it is clear that all the three factors, namely, intrinsic solubility, ability of coordinate water molecules and modifications in protein: protein interactions made by residues present at positions 44 and 59 in the light chain of MAB1 have played significant roles in changing the solution behaviors of the MAB1 variants. These factors have worked in tandem, rather than independently.
Biological activities of MAB1 and variants
Rational biologic drug candidate optimization mandates that improvements in one aspect of a biologic candidate should not be made at the cost of other aspects. In this work, mutation sites were chosen in such a way that the residues present at these sequence positions are unlikely to bind the antigen (Nichols et al., 2015) . To verify that MAB1 variants are indeed biologically active, their antigen binding activities were assessed using ELISA and cell-based bioassays as described in Materials and Methods. The experimental data for MAB1 variants were normalized relative to biological activity of the parent MAB1 which was set at 100%. The results are summarized in Table V . It can be seen that all variants are biologically active in both ELISA and cell-based bioassays. Except for the variant E59Y, all variants show comparable or improved biological activities in both assays. ELISA result for E59Y shows that its biological activity is significantly reduced, but the cell-based bioassay result shows that E59Y is significantly more active than the parent MAB1. Unfortunately, this observation could not be verified because the experiment could not be repeated due to lack of material and resources. For the other MAB1 variants, both ELISA and cell-based bioassays consistently showed that MAB1 variants are at least as active as the parent antibody. Relative potency for V44K was found to be 153% by cell-based assay and 178% by ELISA (Table V) , significantly greater than the parent MAB1. In conclusion, improvements in biophysical properties have also resulted in increased biological activity for MAB1. Relative to the MAB1 parent, the variants are more effective in neutralization of antigen-to-receptor interaction.
Formulation stability of MAB1 and its variants
Stability of MAB1 variants in formulation was assessed by storing them at 4°C, 25°C and 40°C for 3 months. Monomer content (%Monomer) and accumulation of High Molecular Mass Species (%HMMS) as well as Low Molecular Mass Species (%LMMS) were measured using Size Exclusion High Performance Liquid Chromatography (SE-HPLC) (Materials and methods). MAB1 and all its variants remained stable during storage at 4°C (data not shown) and the results for the degradation of samples stored at 25°C and 40°C are summarized in Tables V  (a) and V(b), respectively. Although the data were collected at different time points during the course of this stability study, Tables VI(a) and VI (b) show data from only the initial and final time points. All the variants of MAB1, except V44K, accumulate lower percentages of high molecular mass species (Δ%HMMS) than the parent MAB1 upon storage for 3 months at 25°C. In addition, following variants retain >90% monomer content at the end of three months at 25°C: V44KE59S, E59S, V44K and V44KE59T. All MAB1 variants except V44KE59Y also accumulate lower Δ%HMMS than the parent MAB1 upon storage at 40°C for three months (Table VI( b) ). However, no variant retained more than 90% monomer content at 40°C. As expected, rise in HMMS levels and drops in monomer content are more pronounced in the samples of MAB1 and its variants stored at 40°C than those stored at 25°C. Several variants of MAB1 show greater accumulation of low molecular mass species (Δ%LMMS) than the parent MAB1. Δ% LMMS for the parent MAB1 after storage for three months at 25°C is 1.6%. The corresponding Δ%LMMS values for V44KE59Y, E59Y, E59T and V44KE59T are 12.3%, 7.9%, 48.8% and 2.6%, respectively (Table VI(a)). These observations indicate significantly increased fragmentation of antibody molecules for these variants as compared to the parent MAB1. In particular, E59T shows unusually high levels of low molecular mass species (LMMS) upon storage for three months at 25°C. The %LMMS for this variant rose to 49.1% after 3 months from an initial value of 0.3% at the beginning of the stability experiment (Table VI( a) ). Several MAB1 variants show increased fragmentation at 40°C as well. Δ%LMMS for the parent MAB1 upon storage at 40°C for three months is 5.9% and corresponding increases in MAB1 variants V44KE59Y, E59Y, E59T and V44K are 7.1%, 7.3%, 11.0% and 6.5%, respectively (Table VI  ( b) ). The underlying cause of fragmentation in these variants was not investigated in this work due to lack of material and resources. We speculate that, in some cases, this might have been either due to an accidental contamination by a metal ion that activated potential metal induced cleavage motifs or due to presence of trace amounts of a host cell protease that might have escaped purification. Interestingly, the agent(s) causing increased fragmentation in MAB1 variants are apparently more active at 25°C than at 40°C.
In the end, there were only two MAB1 variants which consistently showed smaller accumulations of HMMS (smaller Δ% HMMS), smaller losses of monomer content (smaller Δ%Monomer) and smaller or equivalent accumulations of LMMS (Δ%LMMS) as compared to the parent MAB1 upon three months storage at both 25°C and 40°C. These MAB1 variant are E59S and V44KE59S (Tables VI(a) and VI(b)). Another variant V44KE59T shows slower degradation than the parent MAB1 at 40°C but not at 25°C.
Overall rankings of MAB1 variants
As described above, MAB1 and its rationally designed single point and double mutants were subjected to a comprehensive battery of experiments for their biophysical performance and biological activity. The data gathered from these experiments was used to rank order the MAB1 variants as shown in Table VII . A given variant scored −1 if it performed significantly worse; scored 0 if it performed similar; and scored +1 if it performed significantly better than the parent MAB1 in an experimental test. No computational data was used for ranking of MAB1 variants. Data on appearance of antibody solutions was not used as well because of its inherently qualitative nature. The criteria for assigning improved, similar or worse performance for the variants were guided by typical uncertainties expected in the data collected in each experiment type. For example, 2°C drops in T m 1 values of E59Y and V44KE59Y in DSC experiments (Fig. 2) were considered significant. For biological activity, the relative activity determined by both ELISA and cellbased assays was considered to assign a composite score. A score of +1 is assigned where both ELISA and cell-based assay show increase activity relative to the parent, while 0 is assigned where the ELISA and cell-based assay do not both show an increase. For example, the activity score is 0 for V44KE59T as the cell-based activity is 87% and ELISA activity is 112%. The storage stability is ranked based on the 40°C data. Furthermore, both Δ%HMMS and Δ%LMMS were added together to obtain values for accumulation of degradation products for MAB1 variants in the formulation stability experiments. Similarly, productivities of MAB1 and its variants in transfection pools of CHO cells were assessed by taking into account their antibody titers and Qp values. Finally, scores across different experiments were summed for each variant, and the total scores were used to rank order the variants. Table VII presents rankings. The variants involving substitution of Ser at position 59, namely, single point mutant E59S and double mutant V44KE59S showed the most comprehensive improvements over the parent MAB1 (Total score for V44KE59S = +7 and for E59S = +6, Table VII ). They performed either similar or better than the parent MAB1 in almost all the experimental tests used in this work. The variant V44KE59S showed improved productivity in CHO cells. It is~150% more concentrate-able than the parent MAB1 and its apparent solubility increased to~160% (Table III) . Its k D is about a fourth (28%) of the k D of the parent MAB1; and its viscosity at 100 mg/ml concentration is less than half of the viscosity of the parent MAB1 (Table IV) . It is also more active and degraded slower than the parent MAB1 in 3 months long formulation stability studies at 25°C and 40°C (Tables IV, VI(a) and VI(b)). The single point mutant E59S also has a total score of +6. Like V44KE59S, the single mutant E59S also performed either similar or better than the parent MAB1 in all experimental tests (Table VII) . Overall, five variants, namely, V44KE59S, E59S, V44KE59Y, E59Y and V44K evaluated here have positive total scores indicating that their biophysical attributes have improved in comparison to the parent antibody. Two variants, namely, V44KE59T and E59T performed similar or worse than the parent MAB1 (Total score for V44KE59T = 0 and for E59T = −1, Table VII); consistent with the predictions from computational modeling.
Discussion and Conclusions
A typical monoclonal antibody molecule contains~1300 residues and a brute-force approach of random mutagenesis and selection to improve solution properties of MAB1 would require screening of 26 000 single point mutations of MAB1 (20 residues for each sequence position) and their innumerable combinations. Such an undertaking would consume large amounts of materials and require heroic efforts on part of the experimentalists. Several strategies can be adapted to substantially reduce these requirements. One of them is to include the knowledge of antibody structure-function and mutate only the residues that are solvent exposed and not part of its complementarity determining region (CDRs) or effector function sites. These exclusions still leave us with several hundreds of potential mutation sites. Furthermore, it is well known that protein surfaces show non-homogeneous distributions of charged and nonpolar residues and mutation of residues at individual solvent exposed sites modify protein surfaces to different extents. Therefore, identifying hot spot residues on an antibody's molecular surface that are capable of significantly altering its solution behavior by experiments alone would still require screening a very large number of single point mutations and their hundreds of potential combinations. Assistance from computational biophysics techniques such as molecular modeling and simulations is needed to further reduce the experimental burden. In this report, Biopharmaceutical Informatics (Kumar et al., , 2017 approach of combining advanced molecular modeling and simulations with biophysical experiments was tested for improving solution behaviors of MAB1 via rational design. Considerations of molecular structure, mutation site selection, biological activity and immunogenicity were included in the computational design process as described in our earlier report (Nichols et al., 2015) . The computational analyses identified two potential locations in the variable portion of light chain of MAB1 for site directed mutagenesis. Initial experimental testings of these sites singly yielded promising results and demonstrated that our design fundamentals are correct (Nichols et al., 2015) . In this work, only seven variants of MAB1 were experimentally tested. This is a greatly reduced number of variants taken for experimental testing. It demonstrates promise of computational antibody engineering. The seven variants explored mutagenesis at the two sites singly as well as simultaneously. A battery of experiments that included appearance, concentrate-ability, apparent solubility, dynamic light scattering, viscosity, formulation stability and biological activity showed that 5 (out of 7, 71%) MAB1 variants resulted in improvement of a %HMMS stands for percent high molecular mass species and Δ %HMMS shows increase in percent high molecular mass species after 3 months of storage at 25°C. %Monomer stands for percent monomer species and Δ% Monomer shows loss of monomer species after 3 months of storage at 25°C. %LMMS stands for percent low molecular mass species and Δ %LMMS shows increase in percent low molecular mass species after 3 months of storage at 25°C. Note that %HMMS, %Monomer and %LMMS add up to 100% (sum of all peaks in an SEC chromatogram). %HMMS peaks include dimers and higher order aggregates of the antibody molecule.
biophysical attributes over the parent antibody. The two variants which performed similar or worse had been already identified by computational modeling. However, these variants were also taken up for experimental testing to provide an all-round confirmation of our approach. Note that all biophysical and biological tests, except those for formulation stability, were performed on non-stressed samples for MAB1 and all of its variants.
Another important feature of this report is that all variants of MAB1 were transfected and produced by using the CHO cells. The products were purified and formulated using the similar platform processes as those followed during GMP production.
A risk-averse pushback to structure-based optimization of solution properties of an antibody drug candidate arises from presumed loss of potency for the candidate and/or increased immunogenicity upon sequence mutation(s) (S. Kumar, personal communications). Therefore, an important finding of this work is that MAB1 variants demonstrated improved biological activities. To our knowledge, this is a first report which demonstrates that it is feasible to simultaneously optimize antibody drug candidates for potency and developability via rational design, without sacrificing either one. Our observations can be rationalized by a rather simplistic chemical reasoning: Consider two variants of a mAB that bind its cognate antigen via identical epitope and paratope residues. One of the variants is hydrophobic and aggregation prone while the other one is more soluble. The first variant shall present reduced effective concentrations for antigen recognition in comparison to the second one. Therefore, reducing aggregation tendency of an antibody while preserving its antigen binding site, may lead to improvements in its biological activities. Consistent with this reasoning, both mutation sites in MAB1 fall in light chain framework regions, FR2 and FR3 and are located in the β-strands at bottom of the light chain CDR2. Note that MAB1 variants with improved biophysical attributes also showed improved productivities in CHO cell lines, in addition to biological activity.
Immunogenicity of MAB1 variants was not experimentally tested in this work. However, immunogenicity considerations were implicitly built into the variant design and selection process. As per information available at the IMGT Repertoire (IG and TR) for human IGLVs (http://www. imgt.org/IMGTrepertoire/Proteins/proteinDisplays.php?species=human& latin=Homo%20sapiens&group=IGLV), human λ light chains at positions corresponding to position 44 in MAB1's light chain often contain Lysine and Argnine residues. Similarly, positions corresponding to E59 in MAB1's light chain often contain Asp, Asn, Ser and Ala. Therefore, MAB1 variants V44K, E59S and V44KE59S have human residues at the positions 44 and 59. Furthermore, immunogenicity risks for MAB1 and its variants were computationally assessed using EpiVax's ISPRI software and results are presented in Tables S1 and S2 of Supplementary material. Overall regulatory T-cell epitope (t-Reg) adjusted epimatrix scores for MAB1 light chain and its variants are low (range = −49 to −60, Table S1 ). Examination of predicted Epi-Bars and tRegs showed that there are no neo-T-cell epitopes (no new Epi-Bars) created for the variants V44K, E59S, E59T, V44KE59S and V44KE59T in comparison to the parent MAB1 light chain (Table S2 ). In case of the variants E59Y and V44KE59Y, a new Epi-Bar was predicted at 59-YRFSGSNSG-67. However, it overlaps with a predicted t-Reg 61-FSGSNSGNT-69 present in all MAB1 and variant light chains. Therefore, it is unclear whether the prediction of new Epi-Bar 59-YRFSGSNSG-67 would actually translate into an increased immunogenicity risk for the MAB1 variants, E59Y and V44KE59Y. In addition to these observations, the reader should keep in mind that immune responses towards biotherapeutics can arise from multiple factors (Singh, 2011) and computational identifications of potential MHC-II binding T-cell epitopes probe only one aspect of this complex biological process.
There are multiple limitations to the work reported here: (i) There was only one antibody to optimize. Applying structure-based biologic drug design approach to a larger number of antibodies will help improve confidence in its robustness. (ii) Apart from the free energy change calculations, molecular modeling and simulations were restricted to the Fv portions of MAB1. Molecular dynamics simulations on the full length antibodies could have yielded additional insights into conformational stabilities, water coordination abilities and allosteric interactions in the MAB1 and its variants, but 
In each experimental test, a MAB1 variant was assigned a score of +1 if its performance improved over the parent MAB1; a score of 0 if its performance remained similar to that of the parent MAB1; and a score of −1 if its performance became worse than the parent antibody. Total score was obtained by summing the scores for each row. A positive total score indicates that the variant performed better than the parent MAB1, and a negative total score indicates that the variant performed worse than the parent MAB1. MAB1 variants V44KE59T and E59T were assigned a score of −1 for Diffusion. The k D values for these variants were not determined because the experimental measurements data obtained showed multimodal behavior (Table IV) . The variant V44KE59T was also assigned a score of −1 for viscosity at 100 mg/ml. Its viscosity value was also not determined because it could not be concentrated to~100 mg/ml in sufficient quantities. Improvements in productivity in the CHO cells were assessed on the basis of antibody titer and Qp values for the following transfection pools: 1A, MAB1; 2B, V44KE59S; 3A, V44KE59Y; 4A, E59Y; 5A, E59T; 6B, E59S; 7A, V44K; and 8B, V44KE59T. Degradation in MAB1 variants was assessed by adding the values of Δ%HMMS and Δ%LMMS upon storage at 40°C for 3 months. For the parent MAB1, degradation products increased by 13.9%. The variants that show increase in degradation products in the range 12.9−14.9% were given a score of 0. The variants outside this range scored either +1 or −1 (see Table VI (b)). Variants E59Y, V44KE59T and E59T wree assigned a score of 0 for biological activity because the activity relative to MAB1 parent was not improved in both the ELISA and cell-based assay. Conversely, all other variants were assigned a score of +1 for biological activity because the activity relative to MAB1 parent was higher by both methods.
they were not performed in this work due to limitations on available computational resources. (iii) This study was focused mostly on biophysical attributes and the MAB1 variants were not assessed for safety and in vivo performance (e.g., PK/PD).
In spite of the above limitations, this is a path-breaking research. To our knowledge, this is the first report where biological activity and biophysical attributes were simultaneously probed for a biologic drug candidate. Five of the seven variants of MAB1 showed improvements on both fronts leading us to conclude that improved solution behavior of MAB1 has resulted in its improved biological activity. Surprisingly, only minor changes in light chain of MAB1 were required to accomplish the goals of this study. This work demonstrates the promise of structure-based biologic drug design and it is anticipated that this report will pave way for similar investigations on other antibodies as well.
Supplementary data
Supplementary data are available at Protein Engineering, Design and Selection online.
